TABLE 1.
Reactivity of the sera from three SIVcpz-infected chimpanzees of Cameroon with distinct V3 and gp41 reference peptidesa
Peptide and virus or group | Serum reactivity
|
|||||
---|---|---|---|---|---|---|
Group M | Group O | Group N | Cam3 | Cam4 | Cam5 | |
V3 | ||||||
Group Mb | 1.54c | 0.26 | 0.23 | 0.31 | 0.17 | 0.56 |
Group O | 0.11 | 1.09 | 0.13 | 0.11 | 0.10 | 0.11 |
Group N | 0.11 | 0.13 | 0.76 | 0.70 | 0.37 | 0.55 |
SIVcpz-gab | 0.11 | 0.12 | 0.56 | 0.51 | 0.30 | 0.58 |
gp41 | ||||||
Group Mb | 1.60 | 1.00 | 0.38 | 0.31 | 0.54 | 0.75 |
Group O | 1.25 | 1.42 | 0.24 | 0.11 | 0.21 | 0.10 |
Group N | 0.22 | 0.61 | 1.13 | 0.97 | 1.20 | 0.85 |
SIVcpz-gab | 0.43 | 0.13 | 0.78 | 0.94 | 1.10 | 1.05 |
The assays were based on the EIA technique as previously described (16).
The peptide is based on an HIV-1 subtype A sequence.
Bold type indicates strong reactivity with the peptide.